Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population

20260 citationsJournal Articlegreen Open Access

Authors

Katelyn Meyer · Massachusetts Executive Office of Health and Human Services

Mckenzie McVeigh · Massachusetts Executive Office of Health and Human Services

Ashley N. Chiara · eHealth Consulting (United States)

Kaelyn C. Boss · eHealth Consulting (United States)

Thomas C. Pomfret · eHealth Consulting (United States)

Kyle Semmel · Massachusetts Executive Office of Health and Human Services

Abstract

At 6 months, MassHealth members showed moderate persistence and adherence to GLP-1 or GLP-1/GIP treatment. Tirzepatide and semaglutide were effective in producing significant weight loss at 6 months among a subgroup of highly persistent and adherent members.

Topics & Keywords

Diabetes Treatment and Management Bariatric Surgery and Outcomes Pharmacology and Obesity Treatment

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: Journal of Managed Care & Specialty Pharmacy

Volume 32, Issue 3, pp. 271-280

DOI: 10.18553/jmcp.2026.32.3.271

Field-Weighted Citation Impact: 0.00